These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 35837977)
1. Real-world Evaluation of the Efficacy of Neoadjuvant DCF Over CF in Esophageal Squamous Cell Carcinoma: Propensity Score-matched Analysis From 85 Authorized Institutes for Esophageal Cancer in Japan. Matsuda S; Kitagawa Y; Takemura R; Okui J; Okamura A; Kawakubo H; Muto M; Kakeji Y; Takeuchi H; Watanabe M; Doki Y Ann Surg; 2023 Jul; 278(1):e35-e42. PubMed ID: 35837977 [TBL] [Abstract][Full Text] [Related]
2. Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003). Yamasaki M; Yasuda T; Yano M; Hirao M; Kobayashi K; Fujitani K; Tamura S; Kimura Y; Miyata H; Motoori M; Shiraishi O; Makino T; Satoh T; Mori M; Doki Y Ann Oncol; 2017 Jan; 28(1):116-120. PubMed ID: 27687307 [TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemotherapy for locally advanced esophageal cancer comparing cisplatin and 5-fluorouracil versus docetaxel plus cisplatin and 5-fluorouracil: a propensity score matching analysis. Nishiwaki N; Noma K; Kunitomo T; Hashimoto M; Maeda N; Tanabe S; Sakurama K; Shirakawa Y; Fujiwara T Esophagus; 2022 Oct; 19(4):626-638. PubMed ID: 35792947 [TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant Triplet Chemotherapy with Docetaxel, Cisplatin plus 5-Fluorouracil versus Docetaxel, Cisplatin plus S-1 for Advanced Esophageal Squamous cell Carcinoma: Propensity Score Matched Analysis. Kitadani J; Ojima T; Hayata K; Goda T; Takeuchi A; Tominaga S; Fukuda N; Nakai T; Yamaue H; Kawai M Oncology; 2024; 102(3):228-238. PubMed ID: 37708864 [TBL] [Abstract][Full Text] [Related]
5. Investigation of operative outcomes of thoracoscopic esophagectomy after triplet chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for advanced esophageal squamous cell carcinoma. Akiyama Y; Iwaya T; Endo F; Chiba T; Takahara T; Otsuka K; Nitta H; Koeda K; Mizuno M; Kimura Y; Sasaki A Surg Endosc; 2018 Jan; 32(1):391-399. PubMed ID: 28664431 [TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemotherapy of triplet regimens of docetaxel/cisplatin/5-FU (DCF NAC) may improve patient prognosis of cStage II/III esophageal squamous cell carcinoma-propensity score analysis. Yamashita K; Katada N; Moriya H; Hosoda K; Mieno H; Katada C; Koizumi W; Hoshi K; Watanabe M Gen Thorac Cardiovasc Surg; 2016 Apr; 64(4):209-15. PubMed ID: 26868531 [TBL] [Abstract][Full Text] [Related]
7. Response to chemotherapy could predict the prognosis of esophageal squamous cell carcinoma treated with neoadjuvant docetaxel, cisplatin, and fluorouracil (DCF) followed by surgery: long-term results in a single institute. Sato Y; Mori K; Atsumi S; Sakamoto K; Oya S; Okamoto A; Urabe M; Miwa Y; Yajima S; Yagi K; Nomura S; Yamashita H; Seto Y Esophagus; 2024 Oct; 21(4):514-522. PubMed ID: 38987434 [TBL] [Abstract][Full Text] [Related]
8. Old age and intense chemotherapy exacerbate negative prognostic impact of postoperative complication on survival in patients with esophageal cancer who received neoadjuvant therapy: a nationwide study from 85 Japanese esophageal centers. Matsuda S; Kitagawa Y; Okui J; Okamura A; Kawakubo H; Takemura R; Muto M; Kakeji Y; Takeuchi H; Watanabe M; Doki Y Esophagus; 2023 Jul; 20(3):445-454. PubMed ID: 36662353 [TBL] [Abstract][Full Text] [Related]
9. Impact of docetaxel in addition to cisplatin and fluorouracil as neoadjuvant treatment for resectable stage III or T3 esophageal cancer: a propensity score-matched analysis. Nomura M; Oze I; Abe T; Komori A; Narita Y; Masuishi T; Taniguchi H; Kadowaki S; Ura T; Andoh M; Kawai R; Uemura N; Ishihara M; Tanaka T; Tajika M; Niwa Y; Muro K; Muto M Cancer Chemother Pharmacol; 2015 Aug; 76(2):357-63. PubMed ID: 26092324 [TBL] [Abstract][Full Text] [Related]
10. Additional Effects of Docetaxel on Neoadjuvant Radiotherapy With Cisplatin/5-Fluorouracil for Esophageal Squamous Cell Carcinoma. Sasaki K; Tsuruda Y; Shimonosono M; Noda M; Uchikado Y; Arigami T; Matsushita D; Mori S; Nakajo A; Kurahara H; Ohtsuka T Anticancer Res; 2022 Aug; 42(8):3905-3911. PubMed ID: 35896244 [TBL] [Abstract][Full Text] [Related]
11. Docetaxel+Cisplatin+5-FU (DCF) Therapy as a Preoperative Chemotherapy to Advanced Esophageal Squamous Cell Carcinoma: A Single-center Retrospective Cohort Study. Umeki Y; Matsuoka H; Fujita M; Goto A; Serizawa A; Nakamura K; Akimoto S; Nakauchi M; Tanaka T; Shibasaki S; Inaba K; Uyama I; Suda K Intern Med; 2023; 62(3):319-325. PubMed ID: 36725064 [TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced esophageal squamous cell carcinoma. Sasaki K; Uchikado Y; Omoto I; Arigami T; Osako Y; Noda M; Okumura H; Maemura K; Higashi R; Yoshiura T; Natsugoe S Cancer Chemother Pharmacol; 2019 Mar; 83(3):581-587. PubMed ID: 30623230 [TBL] [Abstract][Full Text] [Related]
13. Prognostic Advantage of Docetaxel/Cisplatin/ 5-Fluorouracil Neoadjuvant Chemotherapy in Clinical Stage II/III Esophageal Squamous Cell Carcinoma due to Excellent Control of Preoperative Disease and Postoperative Lymph Node Recurrence. Yamashita K; Hosoda K; Moriya H; Katada C; Sugawara M; Mieno H; Komori S; Katada N; Watanabe M Oncology; 2017; 92(4):221-228. PubMed ID: 28110330 [TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Chemotherapy with Divided-dose Docetaxel, Cisplatin and Fluorouracil for Patients with Squamous Cell Carcinoma of the Esophagus. Ojima T; Nakamori M; Nakamura M; Katsuda M; Hayata K; Kato T; Kitadani J; Tabata H; Takeuchi A; Iwahashi M; Yamaue H Anticancer Res; 2016 Feb; 36(2):829-34. PubMed ID: 26851048 [TBL] [Abstract][Full Text] [Related]
15. A propensity score-matched comparison of neoadjuvant chemoradiotherapy with cisplatin-5FU and carboplatin-paclitaxel in locally advanced esophageal squamous cell carcinoma: A Turkish oncology group study. Gürler F; Tay F; Sucuoğlu İşleyen Z; Yerlikaya T; Hendem E; Esen SA; Sütçüoğlu O; Işık D; Niğdelioğlu B; Özen M; Şahin E; Şakalar T; Şengül Samancı N; Alan Ö; Hacıbekiroğlu İ; Algın E; Yılmaz MK; Türk HM; Öksüzoğlu B; Yavuz A; Yüksel O; Bora H; Yazıcı O; Özet A; Özdemir N Cancer Med; 2024 Jul; 13(14):e70002. PubMed ID: 39030808 [TBL] [Abstract][Full Text] [Related]
16. Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study). Nakamura K; Kato K; Igaki H; Ito Y; Mizusawa J; Ando N; Udagawa H; Tsubosa Y; Daiko H; Hironaka S; Fukuda H; Kitagawa Y; Jpn J Clin Oncol; 2013 Jul; 43(7):752-5. PubMed ID: 23625063 [TBL] [Abstract][Full Text] [Related]
17. A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma. Satake H; Tahara M; Mochizuki S; Kato K; Hara H; Yokota T; Kiyota N; Kii T; Chin K; Zenda S; Kojima T; Bando H; Yamazaki T; Iwasa S; Honma Y; Hamauchi S; Tsushima T; Ohtsu A Cancer Chemother Pharmacol; 2016 Jul; 78(1):91-9. PubMed ID: 27193097 [TBL] [Abstract][Full Text] [Related]
18. Long-term outcomes and safety of radical transmediastinal esophagectomy with preoperative docetaxel, cisplatin, and 5-fluorouracil combination chemotherapy for locally advanced squamous cell carcinoma of the thoracic esophagus. Yamagata Y; Saito K; Hirano K; Oya M World J Surg Oncol; 2020 Sep; 18(1):252. PubMed ID: 32962718 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy for superficial esophageal squamous cell carcinoma. Miyawaki Y; Nakajima Y; Kawada K; Okada T; Tokairin Y; Kawano T Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 27001629 [TBL] [Abstract][Full Text] [Related]
20. Utility of initial induction chemotherapy with 5-fluorouracil, cisplatin, and docetaxel (DCF) for T4 esophageal cancer: a propensity score-matched analysis. Makino T; Yamasaki M; Miyazaki Y; Wada N; Takahashi T; Kurokawa Y; Nakajima K; Takiguchi S; Mori M; Doki Y Dis Esophagus; 2018 Apr; 31(4):. PubMed ID: 29190316 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]